TABLE 3.
Toxicity of the pola‐based treatments in all grades and grades 3–4.
| Pola (N = 4) | Pola‐B (N = 5) | Pola‐R (N = 12) | Pola‐BR (N = 30) | |||||
|---|---|---|---|---|---|---|---|---|
| Grades | All | 3‐4 | All | 3‐4 | All | 3‐4 | All | 3‐4 |
| Infection | 0 (0.0%) | 0 (0.0%) | 3 (60.0%) | 2 (50.0%) | 3 (25.0%) | 3 (25.0%) | 12 (40.0%) | 8 (30.8%) |
| Neutropenia | 1 (25.0%) | 0 (0.0%) | 5 (100.0%) | 5 (100.0%) | 7 (58.3%) | 4 (44.4%) | 15 (50.0%) | 10 (40.0%) |
| Anaemia | 3 (75.0%) | 1 (50.0%) | 3 (60.0%) | 3 (60.0%) | 7 (70.0%) | 1 (25.0%) | 23 (76.7%) | 11 (61.1%) |
|
Thrombocytopenia |
2 (50.0%) | 1 (33.3%) | 4 (80.0%) | 3 (75.0%) | 6 (50.0%) | 4 (40.0%) | 18 (60.0%) | 10 (45.5%) |
|
Peripheral neuropathy |
1 (25.0%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) | 2 (18.2%) | 0 (0.0%) | 9 (30.0%) | 0 (0.0%) |
| Lymphopenia | 2 (66.7%) | 1 (50.0%) | 5 (100.0%) | 5 (100.0%) | 10 (83.3%) | 6 (75.0%) | 23 (79.3%) | 16 (72.7%) |